Pegylated interferon alfa-2a and ribavirin treatment for recurrent hepatitis C: Role of steatosis and Body Mass Index

Panminerva Medica

Volumn 51, Issue 2, 2009, Pages 135-136

  Testino, G ^a   Gentile, R ^a   Ansaldi, F ^b   Borro, P ^a   Ravetti, G ^a   Icardi, G ^b   Sumberaz, A ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; PEGINTERFERON ALPHA2A; RIBAVIRIN; ALPHA INTERFERON; RECOMBINANT PROTEIN;

ADULT; BIOPSY; BODY MASS; CLINICAL TRIAL; DRUG COMBINATION; FATTY LIVER; FEMALE; HEPATITIS C; HOSPITALIZATION; HUMAN; LETTER; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDY; RECURRENT DISEASE; TIME; TREATMENT OUTCOME; VIRUS LOAD; COMBINATION DRUG THERAPY; HEPATITIS C, CHRONIC; SEVERITY OF ILLNESS INDEX; TIME FACTOR;

ADULT; ANTIVIRAL AGENTS; BIOPSY; BODY MASS INDEX; DRUG THERAPY, COMBINATION; FATTY LIVER; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON ALFA-2A; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECURRENCE; RIBAVIRIN; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; INTERFERON-ALPHA; RECOMBINANT PROTEINS;

EID: 72949111367     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (8)

1. Liado L, Castellote J, Figueras J. Is retransplantation an option for recurrent hepatitis C cirrhosis after liver transplantation? J Hepatol 2005;42:468-72.
2. Almasio PL, Venezia G, Craxi A. The impact of antiviral therapy on the course of chronic HCV infection. A systematic review. Panminerva Med 2003;45:175-82.
3. Ciesek S, Manns MP, Wedemeyer H. Viral hepatitis after liver transplantation. Which immunosuppressive drugs should be recommended ? Minerva Gastroenterol Dietoi 2007;53:337-50.
4. Fontana M, Ciuffreda D, Moradpour D, Pascual M. Combined antiviral therapy for recurrent hepatitis C virus after liver transplantation. Transplantation 2007;83:525-6.
5. Bergmann JF, De Knegt RJ, Janssen HL. What is on the horizon for treatment of chronic hepatitis C? Minerva Med 2008;99:569-82.
6. Perumalswami P, Kleiner DE, Lutchman G, Heller T, Borg B, Park Y et al. Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. Hepatology 2006;43:780-87.
7. Hjelkrem MC, Torres DM, Harrison SA. Nonalcoholic fatty liver disease. Minerva Med 2008;99:583-93.
8. Ansaldi F, Bruzzone B, Testino G, Bassetti M, Gasparini R, Crovari P et al. Combination hepatitis C virus antigen and antibody immunoassay as a new tool for early diagnosis of infection. J Viral Hepatitis 2006;13:5-10.